Postdoctoral recruitment for lung cancer and lung transplantation team 2025

Introduction to the Mentor 

Professor JIANXING HE, PhD Supervisor, is the Director of the Guangzhou Institute of Respiratory Health and the Director of National Center for Respiratory Medicine. He is also a leading scientist at the Guangzhou National Laboratory, whose primary research focuses on early diagnosis and complex treatment of lung cancer, as well as treatment of end-stage lung diseases such as chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). He has pioneered three internationally recognized technological systems:

1. Tubeless minimally invasive techniques, including autonomous ventilation lung transplantation and tracheal reconstruction (selected by Harvard University for Anesthesiology in 2022 and Tracheal Surgery in 2025).
2. An intelligent screening, diagnosis, treatment, and rehabilitation system for lung cancer.
3. Heterotopic heart-lung combined transplantation.  

Prof. HE innovatively proposed the HE’s Ventilation Mode for thoracic surgery, the theory of secondary injury and prevention in lung transplant donors, and the rapid recovery technology based on TUBELESS for organ transplantation.  

Prof. HE’s team has published a substantial number of internationally influential research achievements, encompassing significant innovations in lung cancer surgery, personalized treatment, and application of cutting-edge technologies. Their work has been featured in top-tier international scholarly journals such as NEJM and The Lancet, with a total of 678 SCI papers published. Among these, 36 papers’ IF＞30, and 72 papers’ IF＞10, underscoring his team’s profound influence and academic value in this field. The cumulative IF of these publications surpasses 5000, with over 60,000 citations. Notably, 21 of these papers have been recognized as ESI Highly Cited Papers, further demonstrating team’s exceptional impact and widespread recognition. These contributions have earned Prof. HE a place in the World’s Top 2% Scientists 2024 Career-long Impact Ranking.

He has also been honored with prestigious titles in China, including National Outstanding Physician, Member of Chinese Academy of Medical Sciences Academic Advisory Committee, Young and Middle-Aged Expert with Outstanding Contributions from the Ministry of Health P.R.China, National Model Teacher, China’s Top Ten Reputable Doctors. Additionally, his remarkable achievements have earned him the National Science and Technology Progress Award (First Prize) for Innovative Team, the National Science and Technology Progress Award (Second Prize), the National Innovation Excellence Award (twice), Ho Leung Ho Lee Prize, and Shulan Medical Award. His contributions have also been acknowledged with more than 20 provincial and ministerial-level accolades, including Guangdong Science and Technology Progress Award (First Prize, twice), the China Anti-Cancer Association Award (First Prize), the Chinese Medical Association Award (First Prize), the Huaxia Medical Association Award (First Prize), the Chinese Hospital Association Research and Innovation Award, and the China Industry-University-Research Collaboration Innovation Award, etc.

Prof. HE’s team comprises over 30 senior thoracic experts, young key members, and a multidisciplinary collaboration group. Annually, they perform more than 12,000 lung cancer surgeries and have extensive experience in nearly 1,000 cases of lung transplants, cardiopulmonary combined transplants, and tracheal transplants. The team has created and developed integrated medical-engineering hardware and software products, including an auxiliary diagnostic tool that achieves over 90% accuracy in early diagnosis of pulmonary nodules smaller than 1 cm, an AI screening tool for lung and mediastinal tumors, a real-time 3D visual surgical operation display system, and a decision-making system for postoperative adjuvant therapy in lung cancer surgeries, significantly improving the long-term survival rates of patients with early-stage lung cancer (primarily pulmonary nodules) and mid-stage lung cancer (primarily tracheobronchial). The team has pioneered multiple lung/tracheal transplant surgeries, transforming many previously untreatable thoracic diseases into treatable conditions.

Desirable Criteria

1. Education and Age:

1. Hold a Ph.D. in oncology, genetics, genomics, immunology, biomedical science, bioinformatics, organ transplantation, artificial intelligence (including statistical machine learning, deep learning, large language models), or related fields, with the degree obtained within the last 3 years. Applicants should generally be under 35 years old.
2. For non-first-time postdoctoral candidates, the previous postdoctoral assessment should be qualified or above.
3. In principle, in-service personnel are not recruited for postdoctoral research.

2. Research Capabilities:

1. Possess a certain level of English reading and writing skills, with experience publishing high-quality SCI papers as the first or corresponding author. Priority will be given to those who have published in internationally renowned journals.

3. Personal Qualities:

1. Physically and mentally healthy, passionate about scientific research, diligent, and reliable. Strong teamwork spirit and independent working ability, with good academic ethics and a rigorous scientific attitude.

4. Professional Background (meet any one of the following):

1. Priority will be given to those with experience in tumor genetics or rejection research in allogeneic/xenogeneic organ transplantation.
2. Strong background in bioinformatics, including computer deep learning, database construction, genomics, and omics algorithm development.
3. Published high-level papers as the first author in fields such as natural language processing, computer vision, or machine learning. Familiarity with large model application technology and experience in smart healthcare research is preferred.

Further Information

1. Salary:

Based on the high-quality papers published (or accepted) within the three years prior to the postdoctoral candidate's entry, the salary is divided into three tiers:  

1. Tier I: Pre-tax annual salary of approximately 450,000 RMB (including the employer’s portion of housing provident fund).  
2. Tier II: Pre-tax annual salary of approximately 390,000 RMB (including the employer’s portion of housing provident fund).  
3. Tier III: Pre-tax annual salary of approximately 330,000 RMB (including the employer’s portion of housing provident fund).  

2. Additional Benefits:

1. Research rewards: Outstanding performance during the postdoctoral period will be rewarded with 50,000 to 150,000 RMB.  
2. Research start-up funding: 200,000 RMB.  
3. Relocation allowance: Postdoctoral fellows who remain at the hospital after completing their term can apply for a 300,000 RMB relocation allowance from Guangzhou City.  
4. Support for applying for Guangzhou’s high-level talent programs. Outstanding postdoctoral fellows who remain at the hospital will be prioritized for inclusion in the "Nanshan Talent Project - Rising Star Program" with corresponding support.  

CONTACT DETAILS

Email: liuseven0801@163.com

Attn: Ms. Liu